Indian Institute of Science

Other

Department of Biotechnology

National Institute of Immunology

Amrita Therapeutics Limited

Avadhesha Surolia

Sarika Gupta

Tandrika Chattopadhyay

Mahendra Pal Singh

Ananda M Chakrabarty

Vaijayanti P Kale

Sidharth Mahali

Deepika Kanojia

Lalita S Limaye

Sunil Kumar Manna

Ashwini Hinge

Anil Suri

Prabhakar Salunkhe

The present invention thus provides microbial products as anticancer agents and pharmaceutical compositions comprising isolated and purified proteins or synthetic peptides, and methods of using them for the treatment of cancer. It is very important to develop new anticancer bioactive peptides having high activity and low toxicity; given that most currently available anticancer therapies either have significant toxicity, and/or are prone to development of resistance.

Anticancer agent

A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.

Method for treating metabolic disorders including type 1 and type 2 diabetes mellitus

Maintenance of quiescent hematopoietic stem and progenitor cells (HSPC) in culture without the addition of exogenous growth factors is an important aspect in clinical hematology. A recent report described the ability of Flt3 receptor-interacting lectin (FRIL) in the maintenance of cord blood (CB) derived progenitors in vitro. Since FRIL is a mannose binding lectin, the effectiveness of four such lectins of well-characterized specificities on the preservation of HSPC of CB origin have been examined. The HSPC preservation activity of lectins was assessed by in vitro colony forming unit (CFU) and long-term culture initiating cell (LTC-IC) assays. It was found that all four lectins had a HSPC preservation activity at least up to 30 days in culture without addition of exogenous growth factors. The results indicate that use of such lectins may provide a cost effective method of HSPC maintenance for clinical use.

Method for preservation of human hematopoietic stem or progenitor cells

Compositions comprising SIA for the treatment of diabetes

Growing community of inventors

New Delhi, India

Avadhesha Surolia